Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGMNASDAQ:MESONASDAQ:OCULNASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMQilian International Holding Group$13.08+1.7%$11.68$5.26▼$16.50$1.27B1.3827,357 shs117,587 shsMESOMesoblast$11.79+1.6%$11.10$5.78▼$22.00$1.51B2.41270,433 shs110,762 shsOCULOcular Therapeutix$9.02+6.6%$7.48$4.79▼$11.78$1.44B1.421.41 million shs2.15 million shsSNDLSNDL$1.32+2.3%$1.35$1.24▼$2.40$346.86M3.451.99 million shs1.98 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMQilian International Holding Group0.00%-2.25%+15.75%+20.83%+1,307,999,900.00%MESOMesoblast0.00%+11.12%+3.33%-12.47%+61.95%OCULOcular Therapeutix0.00%+12.61%+21.12%+19.63%+64.30%SNDLSNDL0.00%+4.37%+1.15%-15.38%-38.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AMESOMesoblast1.7186 of 5 stars3.51.00.00.02.30.80.6OCULOcular Therapeutix3.8589 of 5 stars3.41.00.04.13.42.50.0SNDLSNDL3.4182 of 5 stars3.54.00.00.02.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMQilian International Holding Group 0.00N/AN/AN/AMESOMesoblast 3.00Buy$18.0052.67% UpsideOCULOcular Therapeutix 2.88Moderate Buy$16.2580.16% UpsideSNDLSNDL 3.00Buy$3.63174.62% UpsideCurrent Analyst Ratings BreakdownLatest SNDL, MESO, OCUL, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/31/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMQilian International Holding Group$25.10M50.67N/AN/A$6.10 per share2.14MESOMesoblast$5.67M265.70N/AN/A$4.21 per share2.80OCULOcular Therapeutix$59.65M24.09N/AN/A$0.79 per share11.42SNDLSNDL$927.61M0.37N/AN/A$3.47 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)OCULOcular Therapeutix-$80.74M-$1.15N/AN/AN/A-283.74%-45.18%-30.87%8/6/2025 (Estimated)SNDLSNDL-$127.91M-$0.29N/AN/AN/A-12.11%-8.27%-6.96%7/30/2025 (Estimated)Latest SNDL, MESO, OCUL, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025SNDLSNDL-$0.06-$0.04+$0.02-$0.04$214.60 million$142.38 million3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGMQilian International Holding GroupN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMQilian International Holding GroupN/A3.392.82MESOMesoblast0.211.181.18OCULOcular Therapeutix0.1913.0112.94SNDLSNDL0.105.614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMQilian International Holding GroupN/AMESOMesoblast1.43%OCULOcular Therapeutix59.21%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipBGMQilian International Holding Group58.66%MESOMesoblast18.80%OCULOcular Therapeutix2.30%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AMESOMesoblast80127.78 million103.17 millionOptionableOCULOcular Therapeutix230159.30 million151.71 millionOptionableSNDLSNDL580262.78 millionN/AOptionableSNDL, MESO, OCUL, and BGM HeadlinesRecent News About These CompaniesMarijuana Stocks To Watch With Strong Market PotentialJune 6 at 9:53 AM | marijuanastocks.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 612,495 Shares of SNDL Inc. (NASDAQ:SNDL)May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in SNDL Inc. (NASDAQ:SNDL)May 21, 2025 | marketbeat.com1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court OrderMay 20, 2025 | finance.yahoo.comCanadian Securities Exchange Reports April 2025 Performance FiguresMay 15, 2025 | finance.yahoo.comBNP Paribas Financial Markets Makes New $7.36 Million Investment in SNDL Inc. (NASDAQ:SNDL)May 15, 2025 | marketbeat.comSA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLIMay 5, 2025 | msn.comSNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has IncreasedMay 5, 2025 | seekingalpha.comSNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | insidermonkey.comSNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2025 | finance.yahoo.com3 Marijuana Stocks For The Long Term InvestingMay 2, 2025 | marijuanastocks.comSNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market ReviewMay 2, 2025 | uk.finance.yahoo.comThese Cannabis Companies Are Repurchasing SharesMay 2, 2025 | newcannabisventures.comSNDL Inc. (SNDL) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comSNDL 1Q Loss WidensMay 2, 2025 | marketwatch.comSNDL Inc. Earnings Call Highlights Growth and ChallengesMay 1, 2025 | tipranks.comSNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue EstimatesMay 1, 2025 | zacks.comSNDL Reports Record Q1 2025 Results and Strategic InitiativesMay 1, 2025 | tipranks.comSNDL Reports First Quarter 2025 Financial and Operational ResultsMay 1, 2025 | prnewswire.comSNDL Launches Rise Rewards Loyalty ProgramApril 22, 2025 | prnewswire.comSNDL Inc. to Acquire 32 Cannabis Retail Stores in Strategic ExpansionApril 17, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDL, MESO, OCUL, and BGM Company DescriptionsQilian International Holding Group NASDAQ:BGM$13.08 +0.22 (+1.71%) Closing price 06/6/2025 03:59 PM EasternExtended Trading$13.18 +0.10 (+0.76%) As of 06/6/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Mesoblast NASDAQ:MESO$11.79 +0.18 (+1.55%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$11.56 -0.23 (-1.91%) As of 06/6/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Ocular Therapeutix NASDAQ:OCUL$9.02 +0.56 (+6.62%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$9.17 +0.15 (+1.71%) As of 06/6/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.SNDL NASDAQ:SNDL$1.32 +0.03 (+2.33%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.32 +0.00 (+0.38%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
